Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07NVI
|
|||
| Former ID |
DNCL002244
|
|||
| Drug Name |
CPI-613
|
|||
| Synonyms |
CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1], [2] | |
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 3 | [3] | ||
| B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [1] | ||
| Recurrent adult burkitt lymphoma [ICD-11: 2A85.6; ICD-10: C83.7, C91.8] | Phase 2 | [2] | ||
| Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 1 | [2] | ||
| T-cell lymphoma [ICD-11: 2A90; ICD-10: C86] | Phase 1 | [2] | ||
| Company |
Cornerstone Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28O2S2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
|
|||
| InChI |
1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
|
|||
| InChIKey |
ZYRLHJIMTROTBO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 95809-78-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
49691904, 56179588, 135282095, 136946414, 137262604, 140967897, 141837101, 144115853, 152159590, 162011771, 162205147, 163620890, 163686211, 164045120, 164194087, 174007465, 174531729, 184817440, 189561495, 196394579, 223388754, 223704795, 227310180, 242589862, 248497281, 249814478, 249896071, 252158793, 252160752, 252215198, 252450114
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-ketoglutarate dehydrogenase (OGDH) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT03504423) Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas. U.S. National Institutes of Health. | |||
| REF 4 | A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.